Microelectrode

Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain

Retrieved on: 
Martedì, Maggio 28, 2024
Patient, Doctor of Philosophy, Electrode, Trial of the century, Sale, MD, Research, Neurosurgery, Brain, Microelectrode, Precision, Mount Sinai Health System, Medical device

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the world record for number of electrodes placed on and recording cortical data from a human brain.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the world record for number of electrodes placed on and recording cortical data from a human brain.
  • The previous published record for number of electrodes recording from a human brain was 2,048, demonstrated by Tan et al in 2023 .
  • The device’s modular design allows for multiple arrays to be placed alongside one another, mapping larger regions of brain activity in high resolution.
  • All Precision Neuroscience research conducted at Mount Sinai is conducted by independent investigators without financial ties to the company.

Integer to Showcase Strategic Investments to Support Customers’ Growth and Innovation at Heart Rhythm 2024

Retrieved on: 
Martedì, Maggio 7, 2024
Electrode, IPG, Exhibition, HRS, Heart Rhythm, Integer, Original equipment manufacturer, Microelectrode, CDMO, Acquisition, Electrophysiology, HSR, Medical device

Some examples include market-leading battery technology, finished leads and implantable pulse generators (IPG) for cardiac applications.

Key Points: 
  • Some examples include market-leading battery technology, finished leads and implantable pulse generators (IPG) for cardiac applications.
  • Integer is a leading manufacturer of access and complex catheter access solutions in electrophysiology, including guidewires, transseptal access, diagnostic and ablation technology platforms.
  • Those attending HRS will discover how Integer’s recent strategic investments, particularly the acquisition of Pulse Technologies, are reshaping how Integer serves the world’s leading medical device OEMs and start-ups.
  • These innovations significantly enhance the performance and reliability of medical devices across cardiac rhythm management, neuromodulation, and cardiovascular applications.

MicroCloud Hologram develops a sports training system with a holographic brain-computer interface

Retrieved on: 
Venerdì, Settembre 8, 2023
Exercise, Communication, BCI, Classification, Culture, DSP, FFT, Stroke, Microelectrode, Rehabilitation, Research, Sympathetic nervous system, DSM-IV codes, Movement, Language, SVM, Cerebral cortex, DFT, Signal, Acquisition, Patient, Machine learning, Hearing, Fourier, EEG, MEMS, Diagnosis, ICA, AR, CSP, Common, Medical imaging

Brain-computer interface is a communication technology that does not depend on people's normal peripheral nerves and muscle tissue.

Key Points: 
  • Brain-computer interface is a communication technology that does not depend on people's normal peripheral nerves and muscle tissue.
  • The motion training system of holographic brain-computer interface solves the difficult problem of exercise for patients with functional disorders, and stimulates, extracts and utilizes their active movement willingness.
  • The filtered EEG signal is then identified and matched by intelligent algorithm according to holographic data in holographic data tag library.
  • In the field of rehabilitation medicine, the motion training system of holographic brain-computer interface can effectively assist the rehabilitation training of neuromuscular patients such as stroke or spinal cord injury by controlling robotic arms and exoskeleton robots.

ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants

Retrieved on: 
Mercoledì, Aprile 19, 2023
Epilepsy, Microelectrode, ASC, University, Inflammasome, AIM2, Associate professor, DSM-IV codes, ME, Quality of life, NLRP3, Dystonia, Biomedical engineering, Essential tremor, Wallace H. Coulter Department of Biomedical Engineering, Parkinson's disease, Biomedicine, Patient, NLRP1, Brain, Invention, NLRC4, Therapy, Disease, Medical imaging, Pharmaceutical industry, Medical device, Biomaterial, Medicine

Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia

Key Points: 
  • Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia
    WESTON, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials.
  • In the paper titled, “Activation of inflammasomes and their effects on neuroinflammation at the microelectrode-tissue interface in intracortical implants,” the researchers reported:
    Multiple types of inflammasome sensor molecules (NLRP1, NLRP3, AIM2, and NLRC4) were upregulated following ME implant injury
    NLRP1 and NLRP3, which were upregulated by 48 hours and remained distinctly elevated at 4 weeks, play a vital role in activation of inflammasome complexes during acute and sub-chronic periods following ME-induced injury
    In addition to sensor molecules, ASC and Caspase-1 were persistently elevated throughout the implant duration
    Sustained presence of gasdermin D provides evidence of elevated pyroptosis (“cell death”) occurring at the injury site, which coincided with a decrease in neuronal density
    “Deep brain stimulation is an important therapeutic option to help maintain quality of life in patients with movement disorders whose symptoms are not effectively controlled by medication,” stated Dr. Abhishek Prasad, Associate Professor, the Department of Biomedical Engineering at the University of Miami Miller School of Medicine.
  • “Our results not only demonstrate that continuous activation of inflammasomes contribute to neuroinflammation at the ME-tissue interface, but also reveal the therapeutic potential of targeting inflammasomes to attenuate the foreign body response to cortical implants.”
    “The research published in Biomaterials provides additional support for the therapeutic potential of ZyVersa’s proprietary monoclonal antibody inflammasome ASC inhibitor, IC 100, in neurological injury and disease,” indicated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
  • “Preclinical studies have demonstrated reduced inflammatory activity and/or improved outcomes in two different models of brain injury, spinal cord injury, age-related inflammation Alzheimer’s disease, and multiple sclerosis.”

Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses

Retrieved on: 
Mercoledì, Gennaio 25, 2023
Machine learning, Capital Group Companies, American Neurological Association, Precision, Stroke, Electrode, Capital, Traumatic brain injury, Microelectrode, Tim Draper, FDA, Dementia, Migraine, Hair, Brain, BCI, Medical device, Scotch

The latest investment brings the company’s total funding to $53 million in under two years.

Key Points: 
  • The latest investment brings the company’s total funding to $53 million in under two years.
  • “We imagine a world where devastating neurological conditions – stroke, traumatic brain injury, dementia – are finally treatable,” Michael Mager, CEO of Precision Neuroscience, said.
  • Precision is excited to take on that challenge.”
    According to the American Neurological Association, nearly 100 million people in the U.S. alone suffer from neurological conditions ranging from migraines to Parkinson’s disease.
  • “Precision is pioneering a BCI product that we believe will achieve patient outcomes that were previously thought to be impossible.”

Nebulyft Continues Market Leadership In Anti-Aging Technology With Release Of Flagship N1 Device

Retrieved on: 
Giovedì, Novembre 11, 2021
Titanium, University, Hebei Yuxing Bio-Engineering Co. Ltd, Lightning, Epidermis, CEO, Heat, Technology, N1, Multimedia, Research, Partnership, Microelectrode, National Science Foundation, RF, Temperature, Time, Acne with facial edema, Skin, University of California, Irvine Medical Center, Medical imaging

IRVINE, Calif., Nov. 11, 2021 /PRNewswire/ -- Rebeccatech, the globally distributed, premium manufacturer of Nebulyft anti-aging devices, today announces the release of their new Nebulyft N1 Multipolar RF Anti-Aging Device.

Key Points: 
  • IRVINE, Calif., Nov. 11, 2021 /PRNewswire/ -- Rebeccatech, the globally distributed, premium manufacturer of Nebulyft anti-aging devices, today announces the release of their new Nebulyft N1 Multipolar RF Anti-Aging Device.
  • Following the success of their R1 device, the N1 comes to the market with added Titanium nanotech, a fully ceramic panel for enhanced skin compatibility and enhanced RF feedback sensors for intelligent temperature monitoring.
  • The new N1 device has no equal currently on the market due to its unrivaled surface penetration abilities and non-abrasive, precious metal skin-facing surfaces and patented microelectrode technology.
  • The N1 is now available on the Nebulyft website .